Management of Elevated Liver Function Tests in Pregnancy

Initial Diagnostic Framework

The American Association for the Study of Liver Diseases recommends understanding that normal pregnancy alters reference ranges: albumin decreases, alkaline phosphatase increases (up to 133-418 IU/L in third trimester), while AST, ALT, bilirubin, and GGT remain within non-pregnant ranges 1
Obtaining a detailed medication history including prescribed, over-the-counter, and herbal products is crucial for diagnosis, as recommended by the American College of Gastroenterology 2
Screening for alcohol use and referring for management when appropriate is essential, as advised by the American College of Gastroenterology 2

Trimester-Specific Differential Diagnosis

Intrahepatic cholestasis of pregnancy (ICP) can be diagnosed with elevated serum bile acids (>10 μmol/L non-fasting in third trimester), as recommended by the European Association for the Study of the Liver 1
The American College of Obstetricians and Gynecologists recommends offering ursodeoxycholic acid (UDCA) for bile acids >40 μmol/L to treat maternal pruritus and reduce spontaneous preterm birth risk, and continuing UDCA throughout pregnancy as it is safe in pregnancy and breastfeeding 3, 2

Management by Specific Diagnosis

The European Association for the Study of the Liver recommends continuing UDCA during pregnancy in primary biliary cholangitis and primary sclerosing cholangitis as it is safe and associated with stable liver tests 3, 2
Approximately 50% of women with pre-existing cholestatic liver disease will have worsening or de novo pruritus during pregnancy, but most maintain stable hepatic function, as reported by the American Association for the Study of Liver Diseases 1
Up to 70% of women with pre-existing cholestatic liver disease have postnatal deterioration of serum liver tests, requiring close postpartum monitoring, as advised by the American Association for the Study of Liver Diseases 1
The American College of Gastroenterology recommends performing repeated bile acid measurements when pruritus worsens, as higher levels correlate with reduced gestation length 1, 2
For PSC with worsening cholestasis, the European Association for the Study of the Liver recommends performing ultrasound or MRCP to exclude obstruction or high-grade strictures accessible to endoscopic balloon dilatation 2
The American Association for the Study of Liver Diseases advises avoiding obeticholic acid due to lack of safety data; fibrates may be used after first trimester if benefits outweigh risks 2

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The American College of Gastroenterology recommends screening high-risk women with increased surveillance for gestational diabetes and hypertensive disease using appropriate national protocols 4
Implementing lifestyle modifications including dietary advice as for non-pregnant population is recommended by the American Association for the Study of Liver Diseases 4
Optimizing treatment of metabolic comorbidities before conception and continuing during pregnancy is advised by the American College of Gastroenterology 4
The American Association for the Study of Liver Diseases recommends encouraging breastfeeding in women with MASLD 4

Diagnostic Imaging and Procedures

The European Association for the Study of the Liver recommends that ultrasound and liver elastography are safe at any gestation 1
Note that liver stiffness and controlled attenuation parameter may increase slightly in third trimester as normal physiology, as reported by the American Association for the Study of Liver Diseases 1
The American College of Gastroenterology recommends that MRCP is safe at any gestation and should be used when cholestasis worsens in PSC 3, 1
ERCP can be performed when clinically necessary (fetal radiation <0.1-0.5 mGy, well below 50 mGy threshold), ideally in second/third trimester, as advised by the American Association for the Study of Liver Diseases 1

Critical Pitfalls to Avoid

The American College of Gastroenterology advises not to stop immunosuppressive medications or disease-modifying treatments in women with pre-existing liver disease, as clinical deterioration poses greater risk 4
The European Association for the Study of the Liver recommends not to use obeticholic acid in pregnancy due to lack of safety data 2

Management of Elevated Liver Enzymes in Pregnancy

Initial Assessment

Normal physiological changes of pregnancy can mimic liver disease, including hyperdynamic circulation, palmar erythema, and spider naevi, and normal ranges for serum biochemistry and hematological parameters may alter during pregnancy 5, 6
Consider anti-emetic treatment with first-line options including cyclizine, doxylamine/pyridoxine, prochlorperazine, or promethazine for hyperemesis gravidarum 5

Diagnostic Categories

Pregnancy-Specific Liver Disorders

Control severe hypertension with labetalol, nifedipine, or methyldopa; intravenous therapy may be required for preeclampsia and HELLP syndrome 7
Administer magnesium sulfate to prevent eclamptic seizures in women with severe hypertension for preeclampsia and HELLP syndrome 7
Deliver promptly once maternal coagulopathy and severe hypertension are corrected for preeclampsia and HELLP syndrome 7
Consider intensive care admission for women with encephalopathy, elevated serum lactate, or high Swansea criteria score for acute fatty liver of pregnancy 7
Expedite delivery once coagulopathy and metabolic derangements are treated for acute fatty liver of pregnancy 7
Measure liver tests as they are elevated in 40-50% of severe cases for hyperemesis gravidarum 7
Test for serum bile acid concentrations to identify pregnancies at risk for intrahepatic cholestasis of pregnancy 7
Offer ursodeoxycholic acid (UDCA) for maternal pruritus and to reduce risk of spontaneous preterm birth for intrahepatic cholestasis of pregnancy 8
Recommend delivery from 35 weeks' gestation for women with bile acids >100 μmol/L due to increased stillbirth risk for intrahepatic cholestasis of pregnancy 8

Pre-existing or Coincidental Liver Disease

Optimize health and disease management prior to pregnancy when possible 5, 6
Continue most medications used for chronic liver disease management as stopping could cause clinical deterioration 5, 6

Management Principles

Investigations including ultrasound, MRI, ERCP, endoscopy, and liver biopsy may be performed when benefits outweigh risks 5, 6

Follow-up

Monitor liver function tests until normalization post-delivery 8
Consider genetic screening if there is family history of hepatobiliary disease, early onset, or severe disease 8

Management of Elevated Liver Function Tests in Pregnancy

Diagnostic Approach and Management Strategies

The American College of Gastroenterology recommends measuring serum bile acids, transaminases, bilirubin, alkaline phosphatase, GGT, and platelets in the initial assessment of elevated liver function tests in pregnancy 9
The American Association for the Study of Liver Diseases suggests evaluating for symptoms of liver disease, such as pruritus, right upper quadrant pain, and jaundice, in the diagnostic approach 10
In cases of pruritus, testing for serum bile acids is recommended to identify Intrahepatic Cholestasis of Pregnancy (ICP) 10
For women with hypertension, consideration of pre-eclampsia and HELLP syndrome is necessary, with prompt delivery once maternal coagulopathy and severe hypertension have been corrected 11
The Society for Maternal-Fetal Medicine recommends expedited delivery once coagulopathy and metabolic derangements have been treated in cases of Acute Fatty Liver of Pregnancy (AFLP) 12
Ursodeoxycholic acid (UDCA) should be offered for the treatment of maternal pruritus and reduction of spontaneous preterm birth risk in women with bile acids >40 μmol/L, as recommended by the European Association for the Study of the Liver 10
Delivery planning is crucial, with recommendation of delivery from 35 weeks' gestation for bile acids >100 μmol/L due to increased stillbirth risk, as suggested by the American College of Obstetricians and Gynecologists 9
Post-delivery monitoring is essential, with ensure normalization of liver function tests within 3 months post-delivery, and investigation for underlying liver disease if liver function tests remain abnormal, as recommended by the American Association for the Study of Liver Diseases 13

Management of Elevated Liver Enzymes in Pregnancy

Introduction to Liver Disease Management

Abnormal liver enzymes in pregnant women with pre-existing liver disease require immediate systematic evaluation to distinguish pregnancy-specific disorders from exacerbations of underlying disease, with most chronic liver disease medications continued throughout pregnancy to prevent maternal deterioration 14, 15
Physical findings like palmar erythema and spider naevi occur due to hyperdynamic circulation and hyperestrogenic state, mimicking chronic liver disease 14, 15

Management of Pregnancy-Specific Liver Disorders

Measure serum bile acids weekly from 32 weeks' gestation to identify concentrations >40 μmol/L, which indicate increased risk of adverse outcomes 16, 17
Offer ursodeoxycholic acid (UDCA) for bile acids >40 μmol/L to treat maternal pruritus and reduce spontaneous preterm birth risk 16, 17
Plan elective delivery at 35 weeks' gestation for bile acids >100 μmol/L due to increased stillbirth risk after this gestational age 16, 17
Consider additional therapies for pruritus (rifampicin, cholestyramine, guar gum, activated charcoal) though evidence is limited 16, 17
Monitor bile acids after starting UDCA, recognizing that UDCA itself is measured by enzymatic bile acid assays 16, 17

Diagnostic Imaging and Liver Biopsy

Liver biopsy may be performed when benefits outweigh risks 14, 15

Multidisciplinary Approach

Women with liver diseases of pregnancy associated with increased risk of maternal or fetal morbidity or mortality should be managed by a multidisciplinary team including a physician, obstetrician, and midwife with expertise in the field 16, 17
All women with chronic liver disease or history of gestational liver disease should be offered pre-pregnancy counseling from a team with expertise in managing these disorders 16, 17

Elevated Liver Function Tests in Pregnant Women

Epidemiology and Diagnosis

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-specific liver disease causing elevated LFTs in young pregnant women, affecting 0.4%-10% of pregnancies, with the highest prevalence (up to 5.6%) among Latina women in the United States, according to the American Association for the Study of Liver Diseases 18
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects at least 10% of women of childbearing age and represents the most common chronic liver disease in this population, as stated by the European Association for the Study of the Liver 19, 20

Clinical Characteristics and Management

The American College of Gastroenterology recommends that classic symptom of generalized pruritus without rash, most severe on palms and soles, is a distinguishing feature of ICP, with AST and ALT may be elevated 2-fold to 30-fold 18
Bile acids are the most sensitive diagnostic marker for ICP, with most women without ICP having levels <10 μmol/L, and postprandial bile acid measurements detect higher levels than fasting samples, as suggested by the American Association for the Study of Liver Diseases 18
The European Association for the Study of the Liver suggests that MASLD increases risk of gestational diabetes (17% vs 7% in non-CLD pregnancies) and hypertensive complications (16% vs 3.8-3.9%), and women with known MASLD require increased surveillance using appropriate national screening protocols 19, 20
The American College of Obstetricians and Gynecologists recommends offering ursodeoxycholic acid (UDCA) for bile acids >40 μmol/L to treat maternal pruritus and reduce spontaneous preterm birth risk in confirmed ICP cases 18

Bilirubinuria in Pregnancy: Clinical Significance, Diagnosis, and Management

Clinical Significance & Risks

Bilirubinuria during pregnancy is always abnormal and requires immediate investigation because it signals potentially serious liver disease that threatens both maternal and fetal outcomes. 21
Maternal mortality associated with bilirubinuria‑related liver disease ranges from 1 % to 25 % depending on the underlying condition. 22
Fetal mortality associated with bilirubinuria‑related liver disease ranges from 0.4 % to 23 % depending on etiology. 22

Normal Physiology & Pathologic Threshold

Serum bilirubin concentrations remain within normal limits throughout all trimesters of pregnancy; any elevation or detection of bilirubin in urine therefore indicates pathology requiring urgent evaluation. 21

Initial Laboratory Evaluation (when bilirubinuria is detected)

Obtain serum total and direct bilirubin levels. 21
Measure aminotransferases (AST/ALT). 23
Assess alkaline phosphatase and γ‑glutamyl transferase (GGT). 23
Perform a complete blood count with platelet count. 23
Conduct coagulation studies (PT/INR). 21
Check uric acid and creatinine concentrations. 23

Trimester‑Specific Differential Diagnosis

First Trimester (0–12 weeks)

Hyperemesis gravidarum can cause mild liver test elevations in 40–50 % of cases; bilirubinuria in this setting still warrants evaluation for underlying hepatobiliary disease. 24
Coincidental viral hepatitis or drug‑induced liver injury must be considered. 21

Second/Third Trimester (13–40 weeks)

Intrahepatic cholestasis of pregnancy (ICP) – most common after 30 weeks; bilirubin usually < 5 mg/dL. 22
Preeclampsia/HELLP syndrome – typically after 20 weeks; bilirubin < 5 mg/dL, accompanied by hypertension and proteinuria. 22
Acute fatty liver of pregnancy (AFLP) – third‑trimester presentation; bilirubin < 5 mg/dL but marked coagulopathy, hypoglycemia, and encephalopathy are characteristic. 22

Imaging Strategy

First‑line: Abdominal ultrasound without Doppler – safe at any gestational age and evaluates the biliary tree, liver parenchyma, and vasculature. 21
Second‑line: Magnetic resonance cholangiopancreatography (MRCP) without gadolinium – safe at any gestational age; superior for ductal assessment when ultrasound is nondiagnostic; gadolinium must be avoided because it crosses the placenta. 25
ERCP (when necessary): Fetal radiation exposure is < 0.5 mGy, well below the 50 mGy safety threshold; ideally performed in the second or third trimester. 25

Condition‑Specific Management

Intrahepatic Cholestasis of Pregnancy (ICP)

Measure serum bile acids weekly from 32 weeks gestation onward. 24
Initiate ursodeoxycholic acid (UDCA) 10–15 mg/kg/day in divided doses when bile acids exceed 40 µmol/L; UDCA improves pruritus and may protect against stillbirth. 26
Delivery timing based on bile‑acid concentration:
 > 100 µmol/L → deliver at 36 weeks or at diagnosis if later.
 40–100 µmol/L → deliver between 36–39 weeks.
* < 40 µmol/L → aim for term delivery. 26
For refractory pruritus, consider adjuncts such as rifampicin, cholestyramine, guar gum, or activated charcoal. 24

Preeclampsia / HELLP Syndrome

Correct coagulopathy promptly. 26
Deliver the fetus as soon as maternal stabilization is achieved; delayed delivery increases maternal mortality. 22

Acute Fatty Liver of Pregnancy (AFLP)

Admit to intensive care when encephalopathy, elevated lactate, or a high Swansea criteria score is present. 26
Aggressively correct coagulopathy and metabolic derangements (hypoglycemia, hyperammonemia). 26
Expedite delivery once maternal condition permits. 26
Early referral to a transplant center is advised for severe hepatic failure or lack of improvement after delivery. 22
Consider plasma exchange post‑delivery for severe cases and N‑acetylcysteine for ICU‑level disease. 24

Gallstone Disease

Confirm diagnosis with abdominal ultrasound. 21
If choledocholithiasis is suspected but not visualized on ultrasound, obtain MRCP. 21

Pitfalls to Avoid

Do not assume bilirubinuria is normal in pregnancy; it is never physiologic. 21
Do not delay delivery in preeclampsia, HELLP, or AFLP after maternal stabilization; postponement raises maternal mortality risk. 22
Recognize that AFLP carries a 7–18 % maternal mortality and 9–23 % fetal mortality; the classic triad (coagulopathy, hypoglycemia, encephalopathy) should prompt rapid diagnosis. 22
Bile‑acid levels > 100 µmol/L in ICP markedly increase stillbirth risk after 35 weeks; timely delivery is essential. 26

Multidisciplinary Care

All pregnant patients with bilirubinuria and confirmed liver disease should be managed by a multidisciplinary team including hepatology/gastroenterology, maternal‑fetal medicine, and obstetrics specialists. 24

Post‑partum Follow‑up

Monitor liver function tests until they return to normal, typically within 6 weeks after delivery for pregnancy‑specific liver disorders. 26
If abnormalities persist beyond 6 weeks, evaluate for underlying chronic liver disease. 26
Women with a history of ICP have a 45–70 % risk of recurrence in subsequent pregnancies. 22

Guideline Summary for Liver Disorders in Pregnancy

Diagnostic Approach

Trimester‑Specific Differential Diagnosis

First Trimester (0‑12 weeks)

Second & Third Trimester (13‑40 weeks)

Intrahepatic Cholestasis of Pregnancy (ICP)

HELLP Syndrome

Acute Fatty Liver of Pregnancy (AFLP)

Chronic Viral Hepatitis Management

Hepatitis B

Hepatitis C

Imaging Recommendations

Multidisciplinary Care

Diagnosis and Management of Liver Function Abnormalities in Pregnancy

1. Initial Diagnostic Approach

Obtain a comprehensive liver panel—including AST, ALT, alkaline phosphatase, GGT, total and direct bilirubin, albumin, and platelet count—immediately when any liver test abnormality is suspected. 31, 32
Add pregnancy‑specific tests (non‑fasting serum bile acids, coagulation studies, complete blood count with smear, uric acid, creatinine, and lactate) to the initial work‑up. 31

2. Normal Physiologic Changes in Pregnancy

Alkaline phosphatase rises physiologically to roughly 130–420 IU/L in the third trimester due to placental production. 33, 32, 34
Serum albumin declines throughout gestation, typically to 28–37 g/L in the first trimester. 32, 34
Aminotransferases (AST, ALT), bilirubin, GGT, and bile acids normally remain within non‑pregnant reference ranges; any elevation should be considered pathologic. 33, 32, 34

3. Pattern Recognition and Timing

Classify liver test abnormalities as hepatocellular (predominant transaminase rise) or cholestatic (elevated alkaline phosphatase, bile acids, bilirubin) and then incorporate gestational age to narrow the differential diagnosis. 31

4. Trimester‑Specific Differential Diagnoses

4.1 First Trimester

Hyperemesis gravidarum can cause mild transaminase elevations (generally <300 IU/L) in 40–50 % of severe cases; these abnormalities are usually self‑limiting. 33, 35
Routine screening for viral hepatitis (HAV, HBV, HCV, HEV), herpesviruses, CMV, EBV, autoimmune hepatitis, and drug‑induced liver injury should be performed with appropriate serologies and medication review. 31

4.2 Second and Third Trimester

Intrahepatic Cholestasis of Pregnancy (ICP)

Diagnosis requires a non‑fasting serum bile acid level > 10 µmol/L together with pruritus, most often after 30 weeks gestation. 32
Initiate ursodeoxycholic acid (UDCA) at 10–15 mg/kg/day (divided doses) when bile acids exceed 40 µmol/L to relieve maternal pruritus and lower the risk of spontaneous preterm birth. 32, 35
Delivery timing based on bile‑acid concentration:
 > 100 µmol/L → deliver at 36 weeks or at diagnosis if later. 32
 40–100 µmol/L → aim for delivery between 36–39 weeks. (no citation)
* < 40 µmol/L → aim for term delivery at 39 weeks. (no citation)

HELLP Syndrome

Severe hypertension (systolic > 160 mm Hg or diastolic > 110 mm Hg) should be controlled urgently with oral or IV labetalol, nifedipine, or methyldopa. 35
Non‑severe hypertension (systolic 140–159 mm Hg or diastolic 90–109 mm Hg) is managed with oral labetalol, nifedipine, or methyldopa. 35
Administer magnesium sulfate to prevent eclamptic seizures in women with severe hypertension. 35
Once maternal coagulopathy and severe hypertension are corrected, delivery should be performed promptly, as delayed delivery increases maternal mortality. 35
If severe epigastric or right‑upper‑quadrant pain develops, obtain an abdominal ultrasound to assess for hepatic hematoma or rupture. 35

Acute Fatty Liver of Pregnancy (AFLP)

Admit to intensive care when any of the following are present: encephalopathy, serum lactate > 2.8 mmol/L, MELD score > 30, or Swansea criteria score > 7. 35
Aggressively correct coagulopathy and metabolic derangements (e.g., hypoglycemia, hyperammonemia). 35
Expedite delivery once the mother is stabilized; the mode of delivery should be decided by a multidisciplinary team. 35
Consider plasma exchange after delivery for severe hepatic impairment (evidence limited to small case series). 35
Consider N‑acetylcysteine for ICU‑level disease (limited data but benefits demonstrated in other acute liver failures). 35
Early referral to a transplant center is advised for women with severe hepatic failure or lack of improvement after delivery. 35

5. Imaging Strategy

Abdominal ultrasound without Doppler is the first‑line imaging modality in pregnancy; it safely evaluates the biliary tree, liver parenchyma, and major vessels. 31, 32, 34
Limited Doppler interrogation may be performed when needed, but exposure time should be minimized. 31
If further imaging is required, MRI or MRCP without gadolinium is preferred in all trimesters. 31, 32, 34
Gadolinium contrast must be avoided throughout pregnancy because it crosses the placenta and accumulates in the fetal urinary tract. 31
Endoscopic retrograde cholangiopancreatography (ERCP) can be performed when clinically necessary, with fetal radiation exposure < 0.5 mGy (well below the 50 mGy safety threshold), ideally in the second or third trimester. 32, 34

6. Management of Pre‑Existing Chronic Liver Disease

Approximately 50 % of women with pre‑existing cholestatic diseases (primary biliary cholangitis or primary sclerosing cholangitis) experience worsening or new‑onset pruritus during pregnancy, although most maintain stable hepatic function. 32

7. Critical Pitfalls

Elevated aminotransferases, bilirubin, or bile acids are never normal in pregnancy and must always trigger a systematic investigation. 33, 31
Bilirubin, prothrombin time, GGT, and total bile acids remain within normal limits in healthy pregnant women; any rise warrants evaluation. 33

Evaluation and Management of Elevated ALT in Pregnancy

Initial Diagnostic Workup

Any rise in alanine aminotransferase (ALT) during pregnancy is considered pathologic and warrants immediate systematic investigation. 36
A comprehensive medication history—including over‑the‑counter and herbal products—should be obtained to identify possible drug‑induced liver injury. 36
Systematic alcohol‑use screening is recommended as part of the initial assessment. 36

Imaging Strategy

First‑line imaging: Abdominal ultrasound without Doppler is safe at any gestational age and evaluates the biliary tree, liver parenchyma, and vasculature. 36
Second‑line imaging: Magnetic resonance imaging (MRI) or magnetic resonance cholangiopancreatography (MRCP) without gadolinium is preferred over CT and is safe throughout pregnancy. 36
Endoscopic retrograde cholangiopancreatography (ERCP) may be performed when clinically necessary; fetal radiation exposure is <0.5 mGy, and the procedure is best timed to the second or third trimester. 36

Critical Pitfalls to Avoid

Elevated ALT should never be assumed to be a normal pregnancy finding; it always requires further evaluation. 36

Trimester‑Specific Differential Diagnosis

Hyperemesis Gravidarum (First Trimester)

Severe hyperemesis gravidarum can cause mild ALT elevation (generally <300 IU/L) in 40–50 % of cases and is self‑limiting with supportive care. 36

Intrahepatic Cholestasis of Pregnancy (ICP) (Second/Third Trimester)

Diagnostic criteria: Serum bile acids > 10 µmol/L together with generalized pruritus (especially on palms/soles), usually after 30 weeks’ gestation. 37
Bile acids should be measured weekly from 32 weeks’ gestation. 37
Therapy: Initiate ursodeoxycholic acid (UDCA) 10–15 mg/kg/day in divided doses when bile acids exceed 40 µmol/L to lessen pruritus and reduce the risk of spontaneous preterm birth. [37][38]
Delivery timing based on bile‑acid concentration:
- > 100 µmol/L → schedule delivery at 35–36 weeks.
- 40–100 µmol/L → schedule delivery at 36–39 weeks.
- < 40 µmol/L → aim for term delivery at 39 weeks. 37

HELLP Syndrome (Second/Third Trimester)

Diagnostic criteria: Hemolysis (elevated LDH, schistocytes), AST/ALT 2–10 × upper‑limit of normal, and platelet count < 100 × 10⁹/L, typically after 20 weeks’ gestation. 38
Platelet transfusion is indicated when platelet count falls below 100 × 10⁹/L. 38
Severe hypertension (SBP > 160 mmHg or DBP > 110 mmHg) should be urgently controlled with IV/oral labetalol, nifedipine, or methyldopa. 38
Magnesium sulfate should be administered to prevent eclamptic seizures. 38
Once maternal coagulopathy and severe hypertension are corrected, prompt delivery is recommended; delayed delivery is associated with increased maternal mortality. 38

Acute Fatty Liver of Pregnancy (AFLP) (Second/Third Trimester)

After maternal stabilization, delivery should be expedited to improve outcomes. 38

Post‑partum Follow‑up

Liver function tests should be monitored until they return to normal, typically within three months after delivery. 37
If abnormalities persist beyond three to six weeks, further evaluation for underlying chronic liver disease is warranted. 37
Women with pre‑existing cholestatic liver disease experience post‑natal worsening of liver tests in up to 70 % of cases, necessitating close postpartum monitoring. 38

Management of Pre‑existing Liver Disease in Pregnancy

Immunosuppressive or disease‑modifying therapies should not be discontinued in pregnant women with established liver disease, as cessation poses a greater risk of clinical deterioration. 38